Dear %%first_name%%,
Today I want to talk to you about dividends. Armed with a table compiled by Paul (Rickard) and my own research, I went looking for 10 reliable income-payers, with or without franking, to see if I could get 6-7% in a challenging interest rate world. Check out what I came up with.
In his tenth review for this year, Paul (Rickard) reports on how our model income and growth portfolios performed in October — and things were looking good.
As we know, Aussie medical device companies such as Cochlear and ResMed are two global leaders in their respective spaces and many of you may have followed them. In his article today, James Dunn says that other home-grown device companies are advancing their products and examines 5 that look promising.
In Buy, Sell, Hold, What the Brokers Say, FNArena counted 11 upgrades and 12 downgrades for ASX-listed entities during the week ending Friday 1 November 2019.
And finally, in our “Hot” stock today, CMC Markets’ Chief Market Strategist, Michael McCarthy explains why he likes New Hope Corp (NHC) but doesn’t like CSR (CSR).
If you missed our webinar last Friday, click here to view the recording (and if you have any feedback on the new format, please reply to this email and let us know).
The Switzer Income Conference starts in just one week in Sydney, with Melbourne and Brisbane the following week. To avoid missing out on your complimentary tickets, click on the event you would like to attend below as soon as possible:
Enjoy the read and your week!
Sincerely,
Peter Switzer